PDK1 and cancer: In line our results demonstrate that PDK1 could be an important glycolytic regulator in BRAFV600E driven CRC and that it also could pose a therapeutic vulnerability to cancers driven via fragmented mitochondrial phenotype (Figures 3 & Supplementary Figure 2).